Report Overview

The growth of the IgA Nephropathy disease treatment market can be ascribed to the rise in demand for treatment due to the surge in the number of cases of nephropathic diseases all over the world. Moreover, the pharmaceutical manufacturers have increased expenditure on research and development activities to improve efficiency of the drug and reduce the side effects, which is expected to drive the global IgA nephropathy disease treatment market during the forecast period.

Global IgA Nephropathy Disease Treatment Market - Market Trends & Forecast Report 2028

The global IgA Nephropathy Disease Treatment market was worth USD 130 million in 2021, and it is further projected to reach USD 485.6 million by 2028, at a CAGR of 20.8% during 2022-2028 (forecast period). The growth of the IgA Nephropathy disease treatment market can be ascribed to the rise in demand for treatment due to the surge in the number of cases of nephropathic diseases all over the world. Moreover, the pharmaceutical manufacturers have increased expenditure on research and development activities to improve the efficiency of the drug and reduce the side effects, which is expected to drive the global IgA nephropathy disease treatment market during the forecast period.

IgA Nephropathy Disease Treatment Overview

IgA Nephropathy Disease, also known as Berger's illness is autoimmune kidney disease. IgA Nephropathy Disease is categorized as an orphan disease or rare disease. It causes obstruction in the blood filtration in the minute blood channels of the kidneys. IgA Nephropathy occurs due to an abnormal protein that destroys the filtering unit (glomerulus) present inside the kidneys. Around 20–40% of people suffering from IgA Nephropathy may develop end-stage kidney failure and need dialysis or kidney transplantation. IgA Nephropathy disease treatment comprises medications that aid and manage symptoms, including protein in the urine, high blood pressure, edema, and weaken disease progression.

Global IgA Nephropathy Disease Treatment Market Trends

Growth Driver

Growing Cases of IgA Nephropathy Disease all over the world

The increase in the number of cases of IgA Nephropathy Disease globally has led to the surge in demand for new IgA nephropathy treatments market. Immunoglobulin A (IgA) nephropathy is categorized by the predominant deposition of Immunoglobin A in the glomerular mesangium. Consequently, it remains one of the most common causes of glomerulonephritis throughout the world. Moreover, in the United States, IgA nephropathy accounts for around 10% of biopsies performed in the context of glomerular disease. Throughout the forecast period, the market is expected to be propelled by the augmenting interest in better understanding disease pathophysiology and a dearth of specific therapeutic alternatives. Furthermore, as people are becoming more health-conscious, the market is expected to grow gradually.

Increase in the number of research and development activities By Pharmaceutical Manufacturers

The increase in the number of research and development activities by pharmaceutical manufacturers to improve the efficiency of the drug and reduce the side effects is further propelling the growth of the IgA Nephropathy disease treatment market. In addition, the rising number of drug approvals and launches is expected to further propel the IgA Nephropathy Disease Treatment market's growth rate over the forecast year. Moreover, the market's growth is powered by large-scale investment in developing cutting-edge technologies and increasing the reach in emerging markets. These factors are likely to drive the immunoglobulin A (IgA) nephropathy market growth over the forecast period 2022-2028.

Restraints

Volatility in the Prices of Raw Materials

One of the significant concerns regarding the market growth of the global IgA Nephropathy Disease Treatment market pertains to the escalating volatility in the prices of raw materials. The raw material prices for API and excipients are becoming more volatile. The demand for various materials used in the manufacture of IgA Nephropathy Disease Treatment has increased significantly over the years. As IgA Nephropathy Disease has no exact treatment, the medications are numerous in number. The availability of medications used in IgA Nephropathy Disease Treatment components, including diuretics, ACE inhibitors, ARB's and others, is always changing, thus hampering the growth prospects of the global immunoglobulin A (IgA) nephropathy market.

Impact of COVID-19 on the Global IgA Nephropathy Disease Treatment Market

The global IgA Neuropathy disease treatment market was substantially impacted due to COVID-19 in 2020 in different ways. Lockdown measures were implemented as a result of the COVID-19 epidemic, thus prohibiting patient movement and probable identification. Moreover, the surge in the COVID cases resulted in overburdening the healthcare institutions. Patients undergoing certain treatments experienced a remarkably long turnaround time due to the COVID 19 outbreak. Patients suffering from kidney disease at any stage and kidney transplant receivers did not have much protection against COVID-19 even if they were completely vaccinated. Moreover, several instances of IgA nephropathy relapse were reported following the COVID-19 vaccination treated with corticosteroid therapy. The flash of immune-mediated disease succeeding coronavirus immunization (COVID-19) vaccination was considered quite a rare adverse event following immunization. Relapsing IgA nephropathy (IgAN) cases were reported following either after BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccinations.

Global IgA Nephropathy Disease Treatment Market – By Test

Based on the test, the IgA Nephropathy disease treatment market has been segmented into blood test, urine test, kidney biopsy, iothalamate clearance test, and others. Amidst the segmentation, the urine test segment dominated the IgA Nephropathy disease treatment market in 2021. IgA nephropathy is habitually detected after the patient notices blood in the urine or when a routine test exhibits the presence of protein or blood in the urine. Urine is collected and examined for additional kidney function tests on showing such symptoms. However, blood tests accounted for a considerable market share. A blood test might reflect increased levels of the waste product creatinine in case of kidney diseases.

Global IgA Nephropathy Disease Treatment Market - Regional Insights

Geographically, the global IgA Nephropathy disease treatment market has been segmented into North America, Europe, the Asia-Pacific, Latin America, and the Middle East and Africa. North America dominated the immunoglobulin A (IgA) nephropathy disease treatment market in 2021 in terms of market share in addition to the market revenue. Moreover, it would continue to maintain its dominance over the forecast period owing to the rising demand for IgA nephropathy by scientists and researchers coupled with the rising healthcare expenditure. In addition, the occurrence of foremost key players is likely to further propel the rate of market growth in the region. Contrastingly, the Asia-Pacific is likely to exhibit the highest CAGR over the forecast period 2022-2018.

Competitive Landscape

The global IgA Nephropathy Disease Treatment market is characterized by many local, regional, and global vendors. The key players operating in the global IgA Nephropathy Disease Treatment market are AstraZeneca, Johnson & Johnson Private Limited, Cipla Inc., Siemens Healthcare GmbH, Zydus Cadila, Hikma Pharmaceuticals PLC, LEO Pharma A/S, Fresenius Kabi AG, Accord Healthcare, Abbott, F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Novartis AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Lupin, Alembic Pharmaceuticals Limited, Apotex Inc. and other prominent players. The players maintain their dominance in the market by investing in research and development activities, integrating the latest and advanced technologies into their products, and launching improved products for the customers.

 

Recent Developments

 

• December 2021: Calliditas Therapeutics AB announced that the US Food and Drug Administration (FDA) has approved TARPEYO (budesonide) deferred release capsules to decrease proteinuria among adults with primary immunoglobulin A nephropathy (IgAN) who are at a risk of rapid disease progression, usually a urine protein-to-creatinine ratio ≥1.5g/g. This suggestion is accepted under augmented approval. It has not been recognized whether TARPEYO decelerates kidney function deterioration in patients through IgAN. Sustained approval may be dependent upon corroboration and description of clinical advantage in a assenting clinical trial.1. This approval scripts the fruitful transition for Calliditas into a commercial-stage biopharmaceutical company.

 

• August 2021: Travere Therapeutics, Inc. announced positive topline interim findings for sparsentan, an investigational pharmacological candidate for treating IgA nephropathy. The PROTECT Study met its pre-specified primary efficacy endpoint with statistical importance, indicating a larger than threefold lessening of proteinuria after 36 weeks of treatment, as compared to the active control irbesartan (p<0.0001).

Scope of Report

     

Attribute	Details
Years Considered	Historical data – 2018-2021
	Base Year – 2021
	Forecast – 2022 – 2028
Facts Covered	Revenue in USD Million
Market Coverage	United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Saudi Arabia, United Arab Emirates, South Africa
Product/Service Segmentation	By test, by treatment and by region
Key Players	The key players operating in the global IgA Nephropathy Disease Treatment market are AstraZeneca, Johnson & Johnson Private Limited, Cipla Inc., Siemens Healthcare GmbH, Zydus Cadila, Hikma Pharmaceuticals PLC, LEO Pharma A/S, Fresenius Kabi AG, Accord Healthcare, Abbott, F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Novartis AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Lupin, Alembic Pharmaceuticals Limited, Apotex Inc. and other prominent players.

 

By Test

• Blood Test
• Urine Test
• Kidney Biopsy
• Iothalamate Clearance Test
• Others

By Treatment

• Corticosteroids
• Immunosuppressive Drugs
• ACE Inhibitors and ARBs
• Diet Change
• Therapy

By Region

• • •  
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

1. Research Framework
   1. Research Objective
   2. Product Overview
   3. Market Segmentation
2. Research Methodology
   1. Qualitative Research
      1. Primary & Secondary Research
   2. Quantitative Research
   3. Market Breakdown & Data Triangulation
      1. Secondary Research
      2. Primary Research
   4. Breakdown of Primary Research Respondents, By Region
   5. Assumption & Limitation
3. Executive Summary
4. Global IgA Nephropathy Disease Treatment  Market Insights
   1. Industry Value Chain Analysis
   2. DROC Analysis
      1. Growth Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
   3. Technological Advancement/Recent Development
   4. Regulatory Framework
   5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
5. Global IgA Nephropathy Disease Treatment  Market Overview
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Test
         1. Blood Test
         2. Urine Test
         3. Kidney Biopsy
         4. Iothalamate Clearance Test
         5. Others
      2. By Treatment
         1. Corticosteroids
         2. Immunosuppressive Drugs
         3. ACE Inhibitors and ARBs
         4. Diet Change
         5. Therapy
      3. By Region
         1. North America
         2. Europe
         3. The Asia Pacific
         4. Latin America
         5. The Middle East and Africa
6. North America IgA Nephropathy Disease Treatment  Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Test
      2. By Treatment
      3. By Country
         1. United States
         2. Canada
7. Europe IgA Nephropathy Disease Treatment  Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Test
      2. By Treatment
      3. By Country
         1. Germany
         2. United Kingdom
         3. Italy
         4. France
         5. Spain
         6. Rest of Europe
8. The Asia Pacific IgA Nephropathy Disease Treatment  Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Test
      2. By Treatment
      3. By Country
         1. China
         2. India
         3. Japan
         4. South Korea
         5. Rest of Asia Pacific
9. Latin America IgA Nephropathy Disease Treatment  Market
   1. Market Size & Forecast by Value, 2018-2028
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Test
      2. By Treatment
      3. By Country
         1. Brazil
         2. Mexico
         3. Rest of Latin America
10. The Middle East & Africa IgA Nephropathy Disease Treatment  Market
    1. Market Size & Forecast by Value, 2018-2028
       1. By Value (USD Million)
    2. Market Share & Forecast
       1. By Test
       2. By Treatment
       3. By Country
          1. Saudi Arabia
          2. UAE
          3. South Africa
          4. Rest of Middle East & Africa
11. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. Market Share Analysis, 2021
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Development (Merger, Acquisition, Partnership.)
12. Supplier Analysis
13. Impact of Covid-19 on Global IgA Nephropathy Disease Treatment  Industry
14. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) **
    1. AstraZeneca
    2. Johnson & Johnson Private Limited
    3. Cipla Inc.
    4. Siemens Healthcare GmbH
    5. Zydus Cadila
    6. Hikma Pharmaceuticals PLC
    7. LEO Pharma A/S
    8. Fresenius Kabi AG
    9. Accord Healthcare
    10. Abbott
    11. F. Hoffmann-La Roche Ltd.
    12. Mylan N.V.
    13. Teva Pharmaceutical Industries Ltd.
    14. Sanofi
    15. Novartis AG
    16. Sun Pharmaceutical Industries Ltd.
    17. Aurobindo Pharma
    18. Lupin
    19. Alembic Pharmaceuticals Limited
    20. Apotex Inc
    21. Other Prominent Players
15. Key Strategic Recommendations

 

*Financial information in case of non-listed companies will be provided as per availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

 

List Of Figures

 

Figure 1: Global IgA Nephropathy Disease Treatments Market Segmentation

Figure 2: Global IgA Nephropathy Disease Treatment Industry Value Chain Analysis

Figure 3: Global IgA Nephropathy Disease Treatment Market Size, By Value (USD Million), 2018-2028

Figure 4: Global IgA Nephropathy Disease Treatment Market Share (%), By Test, By Value, 2018-2028

Figure 5: Global IgA Nephropathy Disease Treatment Market Share (%), By Treatment, By Value, 2018-2028

Figure 6: Global IgA Nephropathy Disease Treatment Market Share (%), By Region, By Value, 2018-2028

Figure 7: North America IgA Nephropathy Disease Treatment Market Size, By Value (USD Million), 2018-2028

Figure 8: North America IgA Nephropathy Disease Treatment Market Share (%), By Test, By Value, 2018-2028

Figure 9: North America IgA Nephropathy Disease Treatment Market Share (%), By Treatment, By Value, 2018-2028

Figure 10: North America IgA Nephropathy Disease Treatment Market Share (%), By Country, By Value, 2018-2028 

Figure 11: Europe IgA Nephropathy Disease Treatment Market Size, By Value (USD Million), 2018-2028

Figure 12: Europe IgA Nephropathy Disease Treatment Market Share (%), By Test, By Value, 2018-2028

Figure 13: Europe IgA Nephropathy Disease Treatment Market Share (%), By Treatment, By Value, 2018-2028

Figure 14: Europe IgA Nephropathy Disease Treatment Market Share (%), By Country, By Value, 2018-2028

Figure 15: The Asia-Pacific IgA Nephropathy Disease Treatment Market Size, By Value (USD Million), 2018-2028

Figure 16: The Asia-Pacific IgA Nephropathy Disease Treatment Market Share (%), By Test, By Value, 2018-2028

Figure 17: The Asia-Pacific IgA Nephropathy Disease Treatment Market Share (%), By Treatment, By Value, 2018-2028

Figure 18: The Asia-Pacific IgA Nephropathy Disease Treatment Market Share (%), By Country, By Value, 2018-2028

Figure 19: Latin America IgA Nephropathy Disease Treatment Market Size, By Value (USD Million), 2018-2028

Figure 20: Latin America IgA Nephropathy Disease Treatment Market Share (%), By Test, By Value, 2018-2028

Figure 21: Latin America IgA Nephropathy Disease Treatment Market Share (%), By Treatment, By Value, 2018-2028

Figure 22: Latin America IgA Nephropathy Disease Treatment Market Share (%), By Country, By Value, 2018-2028

Figure 23: The Middle East & Africa IgA Nephropathy Disease Treatment Market Size, By Value (USD Million), 2018-2028

Figure 24: The Middle East & Africa IgA Nephropathy Disease Treatment Market Share (%), By Test, By Value, 2018-2028

Figure 25: The Middle East & Africa IgA Nephropathy Disease Treatment Market Share (%), By Treatment, By Value, 2018-2028

Figure 26: The Middle East & Africa IgA Nephropathy Disease Treatment Market Share (%), By Country, By Value, 2018-2028

Figure 27: Global IgA Nephropathy Disease Treatment Market Share Analysis, 2021

 

List Of Tables

 

Table 1: Global IgA Nephropathy Disease Treatment Market Size, By Test, By Value (USD Million), 2018-2028

Table 2: Global IgA Nephropathy Disease Treatment Market Size, By Treatment, By Value (USD Million), 2018-2028

Table 3: Global IgA Nephropathy Disease Treatment Market Size. By Region, By Value (USD Million), 2018-2028

Table 4: North America IgA Nephropathy Disease Treatment Market Size, By Test, By Value (USD Million), 2018-2028

Table 5: North America IgA Nephropathy Disease Treatment Market Size, By Treatment, By Value (USD Million), 2018-2028

Table 6: 28 North America IgA Nephropathy Disease Treatment Market Size (USD Million), By Country, By Value 2018-2028 

Table 7: Europe IgA Nephropathy Disease Treatment Market Size, By Test, By Value (USD Million), 2018-2028

Table 8: Europe IgA Nephropathy Disease Treatment Market Size, By Treatment, By Value (USD Million), 2018-2028

Table 9: Europe IgA Nephropathy Disease Treatment Market Size (USD Million), By Country, By Value 2018-2028 

Table 10: The Asia-Pacific IgA Nephropathy Disease Treatment Market Size, By Test, By Value (USD Million), 2018-2028

Table 11: The Asia-Pacific IgA Nephropathy Disease Treatment Market Size, By Treatment, By Value (USD Million), 2018-2028

Table 12: 52 The Asia-Pacific IgA Nephropathy Disease Treatment Market Size (USD Million), By Country, By Value 2018-2028 

Table 13: Latin America IgA Nephropathy Disease Treatment Market Size, By Test, By Value (USD Million), 2018-2028

Table 14: Latin America IgA Nephropathy Disease Treatment Market Size, By Treatment, By Value (USD Million), 2018-2028

Table 15: Latin America IgA Nephropathy Disease Treatment Market Size (USD Million), By Country, By Value 2018-2028 

Table 16: The Middle East & Africa IgA Nephropathy Disease Treatment Market Size, By Test, By Value (USD Million), 2018-2028

Table 17: The Middle East & Africa IgA Nephropathy Disease Treatment Market Size, By Treatment, By Value (USD Million), 2018-2028

Table 18: 76 The Middle East & Africa IgA Nephropathy Disease Treatment Market Size (USD Million), By Country, By Value 2018-2028 

Table 19: List of Key Players and Their Offerings

Table 20: Competitive Benchmarking, by Operating Parameters

Table 21        AstraZeneca Company Overview   

Table 22        AstraZeneca Financial Overview    

Table 23        Johnson & Johnson Private Limited Company Overview  

Table 24        Johnson & Johnson Private Limited Financial Overview   

Table 25        Siemens Healthcare GmbH Company Overview   

Table 26        Siemens Healthcare GmbH Financial Overview    

Table 27        Zydus Cadila Company Overview   

Table 28        Zydus Cadila Financial Overview    

Table 29        LEO Pharma A/S Company Overview       

Table 30        LEO Pharma A/S Financial Overview        

Table 31        Accord Healthcare Company Overview     

Table 32        Accord Healthcare Financial Overview      

Table 33        Abbott Company Overview  

Table 34        Abbott Financial Overview   

Table 35        F. Hoffmann-La Roche Ltd. Company Overview   

Table 36        F. Hoffmann-La Roche Ltd. Financial Overview    

Table 37        Mylan N.V. Company Overview      

Table 38        Mylan N.V. Financial Overview      

Table 39        Teva Pharmaceutical Industries Ltd. Company Overview 

Table 40        Teva Pharmaceutical Industries Ltd. Financial Overview  

Table 41        Sanofi Company Overview  

Table 42        Sanofi Financial Overview   

Table 43        Novartis AG Company Overview    

Table 44        Novartis AG Financial Overview     

Table 45        Sun Pharmaceutical Industries Ltd. Company Overview  

Table 46        Sun Pharmaceutical Industries Ltd. Financial Overview   

Table 47        Aurobindo Pharma Company Overview     

Table 48        Aurobindo Pharma Financial Overview      

Table 49        Lupin Company Overview   

Table 50        Lupin Financial Overview